SCHEMBL2904281

SCHEMBL2904281

CC1CCCN1c1nc2c(C(N)=O)cccc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 20/20 0.60
PARP2 Q9UGN5 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5620745 0.77 PARP1 (0.74) PARP1
SCHEMBL5620426 0.76 PARP1 (0.68) PARP1
SCHEMBL5621000 0.75 PARP1 (0.68) PARP1
SCHEMBL631198 0.75 PARP1 (1.00) PARP1PARP2
SCHEMBL630294 0.75 PARP1 (1.00) PARP1PARP2
SCHEMBL5621808 0.75 PARP1 (0.72) PARP1PARP2
SCHEMBL5621895 0.75 PARP1 (0.71) PARP1
SCHEMBL5620966 0.74 PARP1 (0.69) PARP1PARP2
SCHEMBL5621907 0.74 PARP1 (0.66) PARP1
SCHEMBL5620195 0.74 PARP1 (0.65) PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9580410-B2 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1 ABBVIE INC. (US) 2017-02-28 US disclosed
EP-2722046-B1 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1 ABBVIE IRELAND UNLIMITED CO (IE) 2016-12-21 EP disclosed
US-20150148392-A1 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 ABBVIE INC. 2015-05-28 US disclosed
US-8835647-B2 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1 ABBVIE INC. (US) 2014-09-16 US disclosed
EP-2722046-A1 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 1 AbbVie Bahamas Ltd. (BS) 2014-04-23 EP disclosed
US-20140024838-A1 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 ABBVIE INC. (US) 2014-01-23 US disclosed
US-20130123317-A1 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 ABBVIE INC. (US) 2013-05-16 US disclosed
US-8372987-B2 Title compound is Veliparib, a Poly(ADP-ribose) polymerase i.e. PARP inhibitor; anticancer agent ABBVIE INC. (US) 2013-02-12 US disclosed
EP-2212327-A1 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 Abbott Laboratories (US) 2010-08-04 EP disclosed
US-20090099245-A1 2-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 ABBOTT LABORATORIES (US) 2009-04-16 US disclosed
WO-2009049111-A1 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 ABBOTT LABORATORIES (US) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024838-A1 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 TPMT, UACA, GOT2 PARP1 757/4885PARP2 260/4885
US-20090099245-A1 2-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 TPMT, MALT1, GOT2 PARP1 739/4885PARP2 266/4885
US-20150148392-A1 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 TPMT, UACA, GOT2 PARP1 757/4885PARP2 260/4885
US-20130123317-A1 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 TPMT, UACA, GOT2 PARP1 757/4885PARP2 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.